

Instructions for abstracts to be published as free contribution  
in Annals of Hematology 2027 as part of the

### 20<sup>th</sup> International Symposium Acute Leukemias (ISALXX)

Biology and Treatment Strategies - Munich, Germany – March 14-17, 2027

**Deadline for the Submission of Abstracts: November 8, 2026**

**Structured Abstracts** have subheadings in bold type, like a research article: Background, Methods, Results, Conclusions, Keywords, Disclosures, References

**Font:** Calibri 10

**Number of Words:** We recommend a **350-word limit** per abstract

**Abstract Titles:** Abstract titles are in a bold type. **Please be consistent about capitalization and spelling** (British or American English).

**Authors:** Provide full names (given name followed by the family name) and make sure spelling is confirmed for all. **Primary contacts or presenters may appear with an asterisk\***, but other symbols or formatting may not be supported and personal emails are not recommended.

**Affiliations:** Number affiliations in sequential order with one or more contributors. Affiliations include the primary employer or institution name (not abbreviated), and location (city, state or province, country). To save space and reduce duplication omit department names (ie, school, lab, division, institute).

**Disclosures:** Most journals published by Springer Nature require funding and conflict of interest statements. **Each author is responsible for listing support, grants, and any other connections that may be perceived as conflicts**, delivered in a concise and full sentence with the abstract.

**References:** Citations to sources may appear in the body of an abstract with the reference list under the same abstract. Where DOIs are available it may be okay to provide abbreviated references. It's not okay to quote another publication without quotation marks, citation, and reference. Please check any of the links provided by contributors to make sure they are valid. We also recommend following the Journal format consistently, Vancouver (numbered) or Author / Date style.

**Tables:** If needed, tables are in editable text under the body of an abstract, **without color**, and appear no larger than a standard page size to make sure they can be read. However, equations may necessarily be included as figures to maintain alignments.

**Figures:** If needed, figures are also under the body of an abstract, **with or without color**. **Figures need to be sized to fit a standard page**, minimum 86mm, max 178mm (or 3.5in to 7in), high resolution with any fonts embedded, preferably 300 dpi at 100%.

**Low resolution elements will not be improved by resizing or alternate placement.** The easiest way to check is to print concerning pages with a normal office printer at 100% (even if the supplement is an online-only publication).

**Permissions:** Encore presentations may be okay for a conference, but encore publications are not okay without permissions secured in advance from the copyright holder, and even OA-CC-BY publications require citations to the source. Please be aware that supplements are considered promotional or commercial use.

Sample Abstract  
Structured Format with Numbered References

See also: <https://www.springer.com/gp/authorseditors/journal-author/journal-author-helpdesk/preparation/1276>

**Properties of the meeting abstract: Mystery elements explained.**

<sup>1</sup>Kong-sang (Jackie) Chan, <sup>1,2</sup>Victoria Von Waltz et al on behalf of the RSMA workgroup

<sup>1</sup>University of Abstraction, Boston, MA, USA; <sup>2</sup>Royal Society of Meeting Abstracts (RSMA), Wan Chai, Hong Kong, PR China.

**Background:** The Background includes what’s already known, what’s not known about the subject, and describes the purpose for the presentation and aim of study. Avoid using acronyms and jargon.

**Methods:** The Method section shows how the study was carried out [1], with sample sizes (and variations), source of samples (if limited or defined by location), any requirements for inclusion, and duration of the study [2]. Generic drug names are preferable when describing dosage (for example, use acetaminophen as opposed to Tylenol, Johnson & Johnson Consumer, Inc., US) [3].

**Results:** The Results section will have findings and comparisons summarized in complete sentences (see also Table P001-1 or Figure P001-1). The data will be used to define the Conclusion, which may be negative, or may not be significant. If all data can’t be shared in the limited space, then deposit data in an open repository.

**Conclusion:** In addition to briefly summarizing the results, this section may also highlight new or unexpected results and advise on future studies. Statements may only refer to the author conclusions collectively and within a wider perspective rather than offering individual and subjective opinions.

**Keywords:** optional, consistently applied, relevant short phrases, limit of four.

**Clinical Trial Registry:** NCT12345678; <https://clinicaltrials.gov>

**Disclosures:** VVWs employer received a grant from Pharamatown. The authors declared no competing interests.

**Corresponding Author:** Given, middle initial, followed by family name, <https://orcid.org/0000-0000-0000->

References

1. Author J, et al. *Journal Abbrev* 2018; 63 (suppl 6): 8–160. <http://doi.org/00.0000/j.00000000.0000.00000.x>
2. Author B, et al. *Book Title*. Publisher; 2013: 369–377. <http://doi.org/00.0000/b.000000000>
3. Program Name. Version XX. Company Name; 2016. Accessible: <http://www.includethewebaddress.com>
4. ABC Committee. *Guide for Authors*; 2024:1552-1554. <https://www.springer.com/gp/authorseditors/journal-author/journal-author-helpdesk/preparation/1276>


**Table, figure, and caption should be included after references:**

**Tab 1.** Sour Lemon Treatment.

SL Treatment *	Percentage	n
Therapy 1	28.4	712
Therapy 2	71.6	2136

\* SL = Sour Lemon. Modified with permission from ABC Publisher, copyright 2016 [4].

**Fig 1.** Sour Lemon Treatment.



Blue checkers= Therapy 1 (28.4%); Green stripes = Therapy 2 (71.6%).